🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — May 15, 2026

Across 50 overnight SEC filings for May 14-15, 2026, Q1 2026 10-Qs dominate (25+ filings) revealing mixed results for micro/small caps: 18/25 showed revenue declines averaging -25% YoY (e.g., Volato -96%, FreeCast -35%) but 15/25 narrowed net losses via 20-40% opEx cuts, highlighting cost discipline amid topline weakness. SPACs (e.g., Spring Valley IV/III, Range Capital) maintained stable Trust Accounts (~$230M avg, +0.5-1% QoQ from interest) but flagged massive liabilities like $425M subscription expense. Positive standouts include regulatory clearances (Methode), debt refinancings (TPG RE $500M facilities), and fund gains (Global Macro +11.7% NAV, Nestor +12.4% capital). Neutral themes: Board changes/appointments (James Hardie, Heartland/Globalstar AGMs with strong votes), investor conferences (USA Comp, Kinder Morgan May 19-27), monthly credit metrics (Synchrony/Capital One), and 13F snapshots showing institutional conviction in REITs/tech (Hyundai $48M Claros, Silver Lake $3.6B). Portfolio-level: Margin resilience (12 cos gross profit up YoY despite rev down), cash infusions from IPOs/financings (Rank One +$21M, NeoVolta equity +$21M), but cash burns persist (avg op cash use $1-5M). Implications: Tactical buys in loss-narrowing turnarounds; caution on high-burn SPACs; monitor conferences for guidance.

33 high priority 17 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 14, 2026

This week's seven FDA approvals in the Biotech Small-Cap stream comprise 1 NME (PEGFILGRASTIM-PCCG by ACCORD BIOPHARMA INC.), 5 biosimilars (LEVETIRACETAM by MYLAN LABS LTD, HYDROCORTISONE SODIUM SUCCINATE by ZYDUS PHARMS, PALIPERIDONE by I3 PHARMS, BRIMONIDINE TARTRATE by MICRO LABS, Unknown by DR REDDYS LABS LTD), and 1 label expansion (DOLUTEGRAVIR by LACHMAN CONSULTANT SERVICES, INC.), overriding the aggregate '7 Other' mix with detailed classifications. No dominant therapeutic area theme, as approvals span neurology/psychiatry (LEVETIRACETAM, PALIPERIDONE), ophthalmology (BRIMONIDINE TARTRATE), HIV (DOLUTEGRAVIR), and oncology supportive care (PEGFILGRASTIM-PCCG). Highest-conviction signal is ACCORD BIOPHARMA INC.'s NME approval for PEGFILGRASTIM-PCCG (ENNUMO), a bullish catalyst with 8/10 strength and materiality, signaling 5-year NCE exclusivity and strong execution for this small-cap entrant. Overall, 2 bullish signals dominate amid 5 neutrals, favoring selective small-cap upside. Key risk/watch item: Biosimilar entries intensify competitive pressure and potential 30-60% revenue erosion for originators over 2-3 years, though originators unnamed.

7 total filings
· daily

Orphan Drug Approvals — May 14, 2026

The FDA approved 3 Other drugs in the Orphan Drug stream from May 14, 2026 to May 14, 2026, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 3 Others, generating 3 bullish signals and no bearish or neutral outcomes. Argenx BV dominated with label expansions for EFGARTIGIMOD ALFA (VYVGART) and EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC (VYVGART HYTRULO), representing the highest-conviction signal due to dual approvals underscoring pipeline execution in the orphan space and potential for expanded rare disease access. Merus N.V. also secured a label expansion for ZENOCUTUZUMAB-ZBCO (BIZENGRI), adding to the bullish momentum. No dominant therapeutic area theme emerged from the approvals. Key risk/watch item: All commercial details including peak sales estimates, exclusivity, pricing power, and market position remain NOT_DISCLOSED, necessitating monitoring for post-approval uptake and competitive dynamics.

3 total filings
· daily

New Drug Approvals (Original) — May 14, 2026

The May 14, 2026 period saw 7 Other FDA approvals (0 NMEs, 0 biosimilars, 0 label expansions), dominated by fallback classifications including biosimilar-like entries and one each NME/label expansion per analyses. No dominant therapeutic area theme emerged amid diverse assets spanning neurology (LEVETIRACETAM), corticosteroids (HYDROCORTISONE SODIUM SUCCINATE), psychiatry (PALIPERIDONE), ophthalmology (BRIMONIDINE TARTRATE), HIV (DOLUTEGRAVIR), and oncology supportive care (PEGFILGRASTIM-PCCG). Highest-conviction signal is ACCORD BIOPHARMA INC.'s PEGFILGRASTIM-PCCG (ENNUMO) NME approval (strength 8/10, materiality 8/10), implying 5-year NCE exclusivity and strong biologic market entry upside. LACHMAN CONSULTANT SERVICES, INC.'s DOLUTEGRAVIR label expansion provides additional bullish momentum in HIV. Key risk/watch item: Competitive erosion for originators of biosimilars like LEVETIRACETAM (MYLAN LABS LTD entrant) and PALIPERIDONE (I3 PHARMS entrant), with 30-60% potential revenue loss over 2-3 years.

7 total filings
· daily

Federal Construction & Infrastructure Contracts — May 14, 2026

Four federal construction contracts totaling $1,094,837,048 in obligations, all civilian with 0/4 defense-related, highlight commitments across Department of State, Department of Defense, Department of Homeland Security, and Department of the Interior for office buildings, piers, and schools. Dominant theme is firm-fixed-price awards to non-small businesses under full and open competition, led by Caddell Construction Co. (DE), LLC's $698M Department of State office building project. Highest-conviction bullish signal is Caddell and S.J. Amoroso Construction Co., LLC's combined $875M in top-tier materiality awards signaling competitive strength in institutional construction. Key risk is high firm-fixed-price execution exposure across all contracts, compounded by $0 outlays on the three largest ($1.0B total). Watch total outlays and performance through 2027 for funding progress amid CR uncertainty.

4 total filings
· daily

DOD Defense Contracts Intelligence — May 14, 2026

A single $176,962,279 obligation from the Department of Defense to S. J. AMOROSO CONSTRUCTION CO., LLC marks 100% defense spending (1/1 defense-related, 0 civilian) over the May 14, 2026 period. The dominant agency is DOD, with a construction-focused award signaling infrastructure priorities. The highest-conviction bullish signal is the $177M contract win for S. J. AMOROSO CONSTRUCTION CO., LLC (materiality 8/10, strength 7/10). One key risk is potential Continuing Resolution (CR) vulnerability, as the underlying award dates to December 2024, a high-CR-risk window. Investors should monitor execution amid unknown contract pricing risk and competition details.

1 total filings
· daily

DHS Homeland Security Contracts — May 14, 2026

DHS awarded $255,720,951 in civilian contracts (0/3 defense-related) across USCG, ICE, and S&T divisions, highlighting infrastructure construction alongside IT and consulting support. The highest-conviction bullish signal stems from Whiting-Turner Contracting Company's $131.9M firm fixed-price delivery order for Pier Papa recapitalization at USCG Base Charleston, signaling competitive strength in NAICS 236220 despite zero outlays to date. ITC Federal ($62.2M obligation, $45.7M outlayed) and Noblis ($61.7M obligation, $46M outlayed) provide neutral steady revenue from ICE IT platforms and S&T SETA services, respectively, with ceilings up to $80M each. Dominant theme is DHS facilities and tech sustainment amid full and open competition. Key risk: high pricing risk on firm fixed-price structures and stalled outlays on the largest award; watch option exercises and outlay progress through 2026-2027.

3 total filings
· daily

VA Healthcare & Services Contracts — May 14, 2026

The single VA Healthcare & Services contract analyzed totals $133,910,899 in obligations, entirely civilian with zero defense-related activity. V3GATE, LLC, a Service Disabled Veteran Owned Small Business, secured this firm fixed price delivery order from the Department of Veterans Affairs' Technology Acquisition Center NJ for VMware software support, maintenance, professional services, and licenses, spanning 2021-10-01 to 2026-09-30. The dominant agency and sector theme is VA IT/telecom (PSC DA10, NAICS 541519) under SDVOSB set-aside, with $81,673,721 (61%) already outlayed toward a base + all options value of $137.0M. The highest-conviction signal is neutral (4/10 strength), signaling a significant but execution-risky revenue stream estimated at $26.8M annually for V3GATE. A key risk is high pricing exposure from the firm fixed price structure. Investors should watch outlay progress beyond $81.7M, option exercises toward $137M, and performance completion by 2026-09-30.

1 total filings